ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Vertex Pharmaceuticals will pay Alios BioPharma $60 million up front for access to two NS5B polymerase inhibitors in preclinical studies to treat hepatitis C virus (HCV). Alios could reap another $715 million in milestones if both ALS-2200 and ALS-2158 are approved and is slated to receive $35 million this year as the compounds enter Phase I studies. Vertex will also pay for the development of the drug candidates and provide Alios with research funding. Vertex recently gained FDA approval for Incivek, a protease inhibitor used in combination with ribavirin and the injectable drug PEGylated interferon. The addition of the Alios assets will further Vertex’ goal of developing an all-oral combination regimen for the treatment of HCV.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter